Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

Published:2016-03-09 Issue:9 Volume:10 Page:1033-1041
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:ECCOJC

Author:

Ogata Haruhiko,Watanabe Mamoru,Matsui Toshiyuki,Hase Hidenori,Okayasu Motohiro,Tsuchiya Tsuyoshi,Shinmura Yasuhiko,Hibi Toshifumi

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/10/9/1033/13746433/jjw060.pdf

Reference24 articles.

1. Development of the Crohnʼs disease digestive damage score, the Lémann score

2. Inflammatory Bowel Disease

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

4. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

5. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up;Journal of Health Economics and Outcomes Research;2023-11-20

2. Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up;Journal of Health Economics and Outcomes Research;2023-11-20

3. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review;Frontiers in Pharmacology;2023-01-20

4. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia;Biomedicine & Pharmacotherapy;2023-01

5. Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients;Ophthalmology and Therapy;2022-03-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3